Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2014-07-29 Regulatory Filings
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Schnelldiagnostikhersteller treibt Internationalisierung weiter voran/ NanoRepro AG im Zulassungsprozess fur den brasilianischen Markt
Regulatory Filings Classification · 95% confidence The document is a short news release dated July 29, 2014, originating from DGAP (a financial news distribution service). It announces strategic business developments, specifically the expansion into the Brazilian market through a distribution partnership and the submission of registration documents. It mentions expected revenue contributions starting in Q1 2015. This is not a full financial report (10-K or IR), an earnings release (ER) which focuses on results, or a management discussion (MDA). It is a general corporate announcement regarding strategy and market expansion, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item distributed via DGAP, or potentially a strategic update, but RNS is the most appropriate fallback for non-standard announcements distributed via DGAP that aren't explicitly covered elsewhere (like DIRS, DIV, CAP, etc.). Given the content is a strategic business update rather than a mandatory regulatory filing like insider trading or capital change, RNS serves as the best fit among the provided options for a general corporate news announcement.
2014-07-29 German
NanoRepro AG: NanoRepro AG baut Vertriebspartnerschaften weiter aus / Zertifizierungsaudit durch neue Benannte Stelle
Regulatory Filings Classification · 98% confidence The document is a short news release dated July 23, 2014, published via DGAP (a German news distribution service). It discusses business updates, including sales to OEM partners, expansion into Bosnia-Herzegovina, and progress on HIV test certification/launch timeline (end of Q3). It is not a full financial report (10-K or IR), an earnings release (ER) which usually contains specific figures, or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ). Since it is a general corporate announcement detailing strategic decisions, sales progress, and product certification updates, and it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Dividend (DIV), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate news distributed via official channels like DGAP, especially when the content is operational/strategic rather than purely financial results or governance.
2014-07-23 German
Jahresabschluss 2013
Annual Report Classification · 100% confidence The document contains a full balance sheet (Bilanz) and profit and loss statement (Gewinn- und Verlustrechnung) for NanoRepro AG for the fiscal year ending December 31, 2013. It includes detailed financial tables, asset schedules (Anlagenspiegel), and comparative data for the previous year. As it represents the comprehensive annual financial reporting for the company, it is classified as an Annual Report (10-K). FY 2013
2014-06-30 German
NanoRepro AG: NanoRepro AG wechselt Benannte Stelle zur Zertifizierung des HIV Tests / Zulassung Ende des dritten Quartals erwartet
Regulatory Filings Classification · 100% confidence The document is a short news release dated May 28, 2014, originating from DGAP (a financial news distributor). It announces a specific operational update: NanoRepro AG is changing its notified body (Benannte Stelle) for the certification of its HIV test and expects approval by the end of the third quarter. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It concerns a specific operational/regulatory step related to product certification and market entry. Since it is a specific, non-standard announcement that doesn't fit perfectly into categories like CAP, LTR, or DIV, and it is a general regulatory/corporate news item distributed via DGAP, the most appropriate general category is Regulatory Filings (RNS), as it serves as a miscellaneous corporate update that doesn't align with the more specific operational or financial report types listed.
2014-05-28 German
NanoRepro AG: Unternehmen fasst Fu in weiteren Landern/ Diagnostik-Spezialist kurz vor Markteintritt in Jordanien und Bosnien/Umsatz im sechsstelligen Bereich
Earnings Release Classification · 99% confidence The document is a short news release dated May 14, 2014, from NanoRepro AG, announcing international sales expansion into Jordan and Bosnia, resulting in six-figure revenue. It discusses market entry, product portfolio delivery, and future market access talks. The structure (DGAP-News, Corporate News/Finanznachricht) and the content (announcement of business development and revenue achievement) strongly suggest an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it details specific financial outcomes (six-figure revenue) related to operational performance, it aligns best with an Earnings Release (ER) which typically covers key highlights of a period's performance, even if not a formal quarterly report. Given the brevity and focus on recent operational/revenue success, ER is the most appropriate specific classification over the general RNS. FY 2014
2014-05-14 German
Datum:14.04.2014
Audit Report / Information Classification · 98% confidence The document is a formal 'Jahresabschluss' (Annual Financial Statement) for NanoRepro AG for the fiscal year 2013. It includes a balance sheet (Bilanz), notes to the financial statements (Anhang), and details regarding management and supervisory boards. While it is not a full 10-K (which is a specific US SEC filing), it functions as the equivalent annual financial report for a German company. Given the provided categories, '10-K' is the most appropriate classification for a comprehensive annual financial report. FY 2013
2014-04-14 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.